<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HFE897DA68C6E4270BBB8BD28A570F427" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 70 IH: Securing America’s Medicine Cabinet Act of 2021</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2021-01-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 70</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20210104">January 4, 2021</action-date><action-desc><sponsor name-id="B001260">Mr. Buchanan</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To support the advanced manufacturing technologies program of the Food and Drug Administration, to establish National Centers of Excellence in Advanced Pharmaceutical Manufacturing, and for other purposes.</official-title></form><legis-body id="H38D9CE6439DD4171BB7A8C7B7FC043DB" style="OLC"><section id="H609253E947EF4FC580957CC4CB5333EA" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Securing America’s Medicine Cabinet Act of 2021</short-title></quote>.</text></section><section id="H12D8AEE28D214FCA8B0BEECD8BD032E6"><enum>2.</enum><header>Advanced manufacturing technologies program</header><text display-inline="no-display-inline">Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref> et seq.) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H52A6321FAAFC4AA98F825563E38DF582"><section id="HB3F7D6C0ACD04BE6A441EEEDA2807676"><enum>524B.</enum><header>Advanced manufacturing technologies program</header><subsection id="H77E501DB79FF4BA7843DC439D75DB57C"><enum>(a)</enum><header>In general</header><text>Not later than 1 year after the date of enactment of the <short-title>Securing America’s Medicine Cabinet Act of 2021</short-title>, the Secretary shall continue in effect the program to evaluate and approve new drug manufacturing technologies that are included in an application, or supplement to an application, for a drug under subsection (b) or (j) of section 505 of this Act or for a biological product submitted under subsection (a) or (k) of section 351 of the Public Health Service Act.</text></subsection><subsection id="HC4412DD2CFC547EDBBC4670D3B58A807"><enum>(b)</enum><header>Designation</header><text>The Secretary shall designate a method of manufacturing a drug as an advanced manufacturing technology under this section if the drug manufacturer demonstrates that such technology is likely to—</text><paragraph id="H3B1D07FEC25E4A1388B3673E2BCE8A24"><enum>(1)</enum><text>prevent or resolve a drug shortage;</text></paragraph><paragraph id="H8D7FBF5CDDE542BD9F0810FF6DB924E7"><enum>(2)</enum><text>maintain an adequate supply of critical medications for national emergencies; or</text></paragraph><paragraph id="HBDDBC26011844328B087A5D16249D8FE"><enum>(3)</enum><text>promote the adoption of innovative approaches to drug product design and manufacturing.</text></paragraph></subsection><subsection id="H57BA43B6522C4EE091B142340209D084"><enum>(c)</enum><header>Consultation</header><text>If the Secretary designates a method of manufacturing as an advanced manufacturing technology under this section, the Secretary shall take actions to expedite the development and implementation of such method of manufacture for purposes of approval of the application under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act, which may include, as appropriate—</text><paragraph id="H3C7DE4EAB422403D9EF7C01C6657F522"><enum>(1)</enum><text>holding meetings between the sponsor of the application and appropriate Food and Drug Administration staff throughout the development of the technology;</text></paragraph><paragraph id="H7A0C66D6DE2A4209A77CC4C4CE0C038C"><enum>(2)</enum><text>providing timely advice to, and interactive communication with, the sponsor regarding the development of the technology; and</text></paragraph><paragraph id="HDE2AF2CA116B46A68D319908F4EC7C25"><enum>(3)</enum><text>involving senior managers and experienced staff of the Food and Drug Administration, as appropriate, in a collaborative, cross-disciplinary review of the method of manufacturing.</text></paragraph></subsection><subsection id="H929085FA534D43899D3697D9E80A904D"><enum>(d)</enum><header>Evaluation of an Advanced Manufacturing Technology</header><paragraph id="H21BD81CC3A4D4BF69A412AAD4E536A58"><enum>(1)</enum><header>Package</header><text>A sponsor who receives designation of an advanced manufacturing technology under this section shall provide the Secretary with a package of scientific evidence supporting the implementation of the advanced manufacturing technology in a particular context-of-use.</text></paragraph><paragraph id="H02B6ACC6B1E34EBFACDBF9033FEA8437"><enum>(2)</enum><header>Evaluation</header><text>Within 90 days of receiving the package, the Secretary shall determine whether a designated advanced manufacturing technology is validated for the proposed context of use based on the scientific merit the supporting evidence provided by the sponsor.</text></paragraph><paragraph id="HC1C0092EC02E415597DC7DCD7C413DA9"><enum>(3)</enum><header>Effect of Approval</header><text>Upon approval, the same sponsor may rely upon the advanced manufacturing technology for use across multiple manufacturing product lines within the same context-of-use without having to re-submit data to the Secretary validating the underlying technology.</text></paragraph></subsection><subsection id="H4CC92E187E1D4DE193985D7D9E40C0AF"><enum>(e)</enum><header>Implementation and Reporting</header><paragraph id="H2F99FD4E1DB841DE95A94D5973D9F2E4"><enum>(1)</enum><header>Public meeting</header><text>The Secretary shall publish in the Federal Register a notice of a public meeting to be held no later than 1 year after the date of enactment of the <short-title>Securing America’s Medicine Cabinet Act of 2021</short-title> to discuss and obtain input and recommendations from stakeholders regarding the goals and scope of, and a suitable framework and procedures and requirements for, the program under this section.</text></paragraph><paragraph id="HEB02E6C95AE44B5390539306FCF38DF7"><enum>(2)</enum><header>Program guidance</header><text>The Secretary shall—</text><subparagraph id="H0F26EED85D8A444E95ADF43C35C20572"><enum>(A)</enum><text>not later than 1 year after the date of enactment of the <short-title>Securing America’s Medicine Cabinet Act of 2021</short-title>, issue draft guidance regarding the goals and implementation of the program under this section; and</text></subparagraph><subparagraph id="H53EE4C50282145A58A71779A04A951C1"><enum>(B)</enum><text>not later than 2 years after the date of enactment of the <short-title>Securing America’s Medicine Cabinet Act of 2021</short-title>, issue final guidance with respect to the implementation of such program.</text></subparagraph></paragraph><paragraph id="H4C9C415FBFF448539D7D9A3F33AEAA27"><enum>(3)</enum><header>Report</header><text>The Secretary shall make available on the internet website of the Food and Drug Administration an annual report on the progress of the program under this section.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="HB350C47045044B93B83390B5C3E249C5"><enum>3.</enum><header>National Center of Excellence in Advanced Pharmaceutical Manufacturing</header><text display-inline="no-display-inline">Chapter X of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/391">21 U.S.C. 391</external-xref> et seq.) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H9AD01C03406F4444838C7F157A48D0A8"><section id="HAE27BA0EBAB1453885CF40532E69E6C5"><enum>1015.</enum><header>National Center of Excellence in Advanced Pharmaceutical Manufacturing</header><subsection id="HD8C9402E612B4A5DB4D42316C64E33B2"><enum>(a)</enum><header>In general</header><text>The Secretary shall designate institutions of higher education as National Centers of Excellence in Advanced Pharmaceutical Manufacturing, including continuous pharmaceutical manufacturing.</text></subsection><subsection id="H7E2F81B627F24C87AA086E6EDFE2DB0C"><enum>(b)</enum><header>Eligibility</header><text>To be eligible for designation under subsection (a) an entity shall—</text><paragraph id="HFC488AF005E147C1AF38142EAE4EF093"><enum>(1)</enum><text>be an institution of higher education;</text></paragraph><paragraph id="H939CB328E40A46FEBA563AD45F430050"><enum>(2)</enum><text>demonstrate—</text><subparagraph id="H392F5BBB2486450FBCE8BF110E78BE07"><enum>(A)</enum><text>the physical and technical capacity for research and development of advanced pharmaceutical manufacturing;</text></subparagraph><subparagraph id="HC4003A36DBD342D9BEAD7D88BCF12244"><enum>(B)</enum><text>a record of transferring scientific knowledge to the marketplace;</text></subparagraph><subparagraph id="H0E87A68E39E441DD9E6C596B5E75D349"><enum>(C)</enum><text>scalable manufacturing knowledge, which may be through collaborations of other institutions of higher education, biopharmaceutical manufacturers, or other entities;</text></subparagraph><subparagraph id="H032EF55C5674476EA28C4213E5AE21E7"><enum>(D)</enum><text>the ability to train a future workforce for research on and implementation of advanced pharmaceutical manufacturing; and</text></subparagraph><subparagraph id="HA1D9B25107E544CCB4DC492D42E51972"><enum>(E)</enum><text>the ability to support Federal agencies with technical assistance for advanced pharmaceutical technologies, with an emphasis on creating a secure national pharmaceutical stockpile and the ability to rapidly address drug shortages; and</text></subparagraph></paragraph><paragraph id="H36F1585A8FE846A9B1446B09A7EC57E8"><enum>(3)</enum><text>submit an application to the Secretary at such time, in such form, and in such manner as the Secretary may require. </text></paragraph></subsection><subsection id="HF43746D89D964B76B72C2B54B34B0C85"><enum>(c)</enum><header>Termination</header><text>The Secretary may terminate the designation of an entity designated under subsection (a) upon a determination that the entity no longer meets the requirements of subsection (b). </text></subsection><subsection id="HA42CCCE5BE204152B16C9066D7BAAFFE"><enum>(d)</enum><header>Annual report</header><text>Not later than 1 year after the date on which the first designation is made under subsection (a), and annually thereafter, the Secretary shall submit a report to Congress on the activities of the entities designated under such subsection. </text></subsection><subsection id="H537F88B1EB7F43FC9C40C2255FF975B2"><enum>(e)</enum><header>Authorization of appropriations</header><text>To carry out this section, there are authorized to be appropriated $100,000,000 for the period of fiscal years 2022 through 2025.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

